Pirfenidone in combination with glucocorticoids provides a potential therapeutic strategy for grade 2 or grade 3 radiation-induced lung injury, addressing the unmet clinical need for effective antifibrotic therapy in patients receiving thoracic radiotherapy. Further investigation is needed to validate these findings in patients with worse radiation-induced lung injury than was studied here.
[Articles] Pirfenidone for grade 2 and grade 3 radiation-induced lung injury: a multicentre, open-label, randomised, phase 2 trial
The Lancet Oncology | | Zan Hou, Baiqiang Dong, Qiwei Yao, Hualin Chen, Qiuju Shao, Minying Li, Jianyang Wang, Keying Chen, Zhengfei Zhu, Fang Peng, Shihong Wei, Xiao Hu, Jiancheng Li, Meilian Liu, Bin Xu, Siming Zheng, Nan Bi, Shuohan Zheng, Qingqing Xu, Biqi Chen, Chenfei Wu, Rui Li, Wei Chen, Xin Liu, Yuchen Tian, Xuan Li, Suping Guo, Lei Zhao, Yujia Zhu, Ling Cai, Qiaoqiao Li, Li Li, Huilan Zhang, Chen Hu, Luhua Wang, Qiwen Li, Baoqing Chen, Ming Chen
Topics: radiation, clinical-trials, research